Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.22.62 extracted from

  • Diaconu, I.; Ballard, B.; Zhang, M.; Chen, Y.; West, J.; Dotti, G.; Savoldo, B.
    Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells (2017), Mol. Ther., 25, 580-592 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.22.62

Application

Application Comment Organism
medicine B cell lymphoid malignancies are treated with T cells expressing the chimeric antigen receptor (CAR) specific for the CD19 antigen (CD19.CAR-Ts). The inducible caspase-9 safety switch, i.e. a modified human caspase-9 fused to the human FK506 binding protein, can eliminate CD19.CAR-Ts in a dose-dependent manner, allowing either a selective containment of CD19.CAR-T expansion in case of cytokine release syndrome or complete deletion on demand granting normal B cell reconstitution Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P55211
-
-